Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03239470
Recruitment Status : Active, not recruiting
First Posted : August 4, 2017
Last Update Posted : February 2, 2021
Sponsor:
Collaborators:
Autoimmunity Centers of Excellence
Rho Federal Systems Division, Inc.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Tracking Information
First Submitted Date  ICMJE August 2, 2017
First Posted Date  ICMJE August 4, 2017
Last Update Posted Date February 2, 2021
Actual Study Start Date  ICMJE October 10, 2017
Actual Primary Completion Date December 10, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 22, 2017)
Number of Significant Events as Defined by Grade 3 or higher adverse event(s) by Week 52 [ Time Frame: Baseline (Visit 0) to Week 52 ]
Severity [Adverse Events (AEs) and Serious Adverse Events (SAEs)] will be reported using NCI-CTCAE grading criteria. Reference: the National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 http://ctep.cancer.gov/reporting/ctc.html.
Original Primary Outcome Measures  ICMJE
 (submitted: August 2, 2017)
Number of Significant Events as Defined by Grade 3 or higher adverse event(s) by Week 52 [ Time Frame: Baseline (Visit 0) to Week 52 ]
Severity (Adverse Events [AEs] and Serious Adverse Events [SAEs]) will be reported using NCI-CTCAE grading criteria. Reference: the National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 http://ctep.cancer.gov/reporting/ctc.html.
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
Official Title  ICMJE A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Pemphigus (APG01)
Brief Summary

T cells, a type of white blood cell called a lymphocyte, play an important role in the immune system. One subtype, the regulatory T cell (Treg) helps to regulate the immune system and may provide protection against the development of autoimmune disease. The hope is that these naturally occurring Treg cells can be utilized for the treatment of autoimmune disease and potentially replace the use of chronic immunosuppressive therapies that are associated with multiple side effects. There has been a small study showing safe administration of Tregs with decreased disease activity in patients with insulin-dependent diabetes. Tregs are being studied in lupus, cancer and organ transplantation.

This phase I trial will be conducted as an open-label, dose-escalation, multicenter trial in adult participants with active pemphigus.The purpose of this study is to test the safety and effect of Treg therapy in participants who have skin (cutaneous) involvement due to pemphigus.

Detailed Description

Up to 12 adults between the ages of 18 and 75 years of age who have been diagnosed with pemphigus and meet all other entry criteria will be enrolled to receive one infusion of their own expanded Tregs at one of the following doses:

  • 1.0 x 10^8 PolyTregs or
  • 2.5 x 10^8 PolyTregs.

Safety, disease activity, and mechanism of action will be assessed over a three year period, using biospecimens from blood and skin. Study therapy administration will occur during an overnight stay, followed by 2 weekly visits, then monthly visits from Week 8 to Week 12, then quarterly visits from Week 26 to Week 52, then twice a year visits until Week 156.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Pemphigus Foliaceus
  • Pemphigus Vulgaris
Intervention  ICMJE
  • Biological: Cohort 1: 1.0 x 10^8 PolyTregs
    Each participant will receive a target cell dose of 1.0 x 10^8 polyclonal Tregs.
    Other Names:
    • Polyclonal Regulatory T Cells
    • autologous PolyTregs
    • CD4+CD127lo/negCD25+ PolyTregs
  • Biological: Cohort 2: 2.5x10^8 PolyTregs
    Each participant will receive a target cell dose of 2.5x10^8 polyclonal Tregs.
    Other Names:
    • Polyclonal Regulatory T Cells
    • autologous PolyTregs
    • CD4+CD127lo/negCD25+ PolyTregs
Study Arms  ICMJE
  • Experimental: Cohort 1: 1.0 x 10^8 PolyTregs
    A single intravenous infusion of 1.0 x 10^8 PolyTregs will be administered.
    Intervention: Biological: Cohort 1: 1.0 x 10^8 PolyTregs
  • Experimental: Cohort 2: 2.5x10^8 PolyTregs
    A single intravenous infusion of 2.5x10^8 PolyTregs will be administered.
    Intervention: Biological: Cohort 2: 2.5x10^8 PolyTregs
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 27, 2020)
4
Original Estimated Enrollment  ICMJE
 (submitted: August 2, 2017)
12
Estimated Study Completion Date  ICMJE December 2022
Actual Primary Completion Date December 10, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Ability to provide informed consent;
  • Diagnosis of Pemphigus Vulgaris (PV) or Pemphigus Foliaceus (PF), defined by H&E staining (e.g., Haemotoxylin and Eosin) and direct immunofluorescence staining of skin biopsy at any time prior to enrollment;
  • Pemphigus treated with systemic corticosteroids within the 2 years prior to screening (historic or current), or treated with rituximab ≥ 12 months prior to screening;
  • Presence of:

    • anti-Dsg3 antibodies (>20.0 U/ml) at screening visit consistent with diagnosis of pemphigus vulgaris or,
    • anti-Dsg1 antibodies (>20.0 U/ml) at screening visit consistent with diagnosis of pemphigus foliaceus.
  • Active of PV or PF as defined by Pemphigus Disease Area Index (PDAI) overall activity score 3-10 at screening visit, and PDAI overall activity score 1-12 at baseline visit;
  • Positive test for Epstein-Barr Virus (EBV) antibody;
  • Adequate venous access to support draw of 400 ml whole blood and infusion of investigational therapy; and
  • An absolute Treg count of ≥ 42 cells/μL within 6 weeks prior to whole blood collection at Week -2 (i.e., 2 weeks prior to planned PolyTreg Infusion).

Exclusion Criteria:

  • Initiation of systemic corticosteroid therapy, prednisone dose > 25 mg/d (or equivalent) or change in prednisone dose within 4 weeks prior to screening;
  • Addition of a new medication, or change in the dose of any background medication used to treat any aspect of pemphigus within the timeframes listed below. Specifically:

    • methotrexate, mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine or dapsone within the 6 weeks prior to screening or in the time between screening and study drug infusion,
    • intravenous Immunoglobulin (IVIG) within 12 weeks prior to screening or in the time between screening and study drug infusion (subjects on IVIG must be on stable dose for at least 12 weeks prior to screening),
    • treatment with cyclophosphamide within 12 weeks prior to screening or in the time between screening and study drug infusion.
  • Doses of background medications at screening:

    • methotrexate > 25 mg/week,
    • mycophenolate mofetil > 3000 mg/d,
    • mycophenolic acid > 1080 mg/bid,
    • azathioprine > 200 mg/d,
    • cyclosporine > 2 mg/kg/d,
    • dapsone >250 mg/d,or
    • intravenous immunoglobulin (IVIG) > 4mg/kg monthly.
  • Use of rituximab within the 12 months prior to screening;
  • Change in dosing frequency, concentration, or applied surface area of topical steroids and/or topical calcineurin inhibitors within 2 weeks prior to screening;
  • Paraneoplastic pemphigus;
  • Pemphigus erythematosus;
  • Pemphigus vegetans;
  • Immunoglobulin A (IgA) pemphigus;
  • Drug-induced pemphigus;
  • Blood donation within 10 weeks prior to baseline visit (Day 0);
  • Hemoglobin < 10 g/dL;
  • White blood cell (WBC) count < 3,000/ mm^3 (equivalent to < 3 x10^9/L);
  • Lymphocyte count < 800/mm^3 (equivalent to < 0.8 x10^9/L);
  • Absolute neutrophil count < 1,500/mm^3 (equivalent to < 1.5 x10^9/L);
  • Platelets < 100,000/mm^3 (equivalent to < 100 x 10^9/L);
  • Liver function test [aspartate aminotransferase (AST)], alanine aminotransferase (ALT), or alkaline phosphatase (ALK)] results that are ≥ 2 times the upper limit of normal (ULN);
  • Direct bilirubin > ULN;
  • End stage renal disease [estimated glomerular filtration rate (eGFR) < 20 ml/min/1.73m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation];
  • At or within three months of screening:

    • a positive QuantiFERON(R)-TB Gold test or positive purified protein derivative tuberculin skin test (PPD) [>5mm induration, regardless of Bacille Calmette Guerin (BCG) vaccine administration] unless completion of treatment has been documented for active Tuberculosis (TB),
    • an indeterminate QuantiFERON (R)-TB Gold test unless followed by a subsequent negative PPD or negative QuantiFERON(R)-TB Gold test as well as a consultation with and clearance by local infectious disease (ID) department.
  • Recent or ongoing active bacterial, viral, fungal, or opportunistic infections requiring systemic anti-infective therapy;
  • Evidence of current or prior infection with human immunodeficiency virus (HIV), hepatitis B [as assessed by HBsAg and anti-hepatitis B core antigen (HBc) Ab] or hepatitis C [as assessed by anti-Hepatitis C Virus (anti-HCV) Ab];
  • Detectable circulating EBV or Cytomegalovirus (CMV) genomes or active infection;
  • Chronic infection that is currently being treated with suppressive anti-infective therapy, including but not limited to tuberculosis, pneumocystis, CMV, herpes zoster, and atypical mycobacteria, with the exception of historical orolabial or localized cutaneous herpes simplex infections treated with suppressive anti- viral therapy;
  • Receipt of a live-attenuated vaccine within 12 months prior to screening;
  • Concomitant malignancies or a history of malignancy, with the exception of completely treated basal cell carcinoma of the skin;
  • Pregnancy;
  • Lactating or breastfeeding;
  • Unwilling or unable to use reliable method(s) of contraception:

    • For females of child-bearing potential, from four weeks prior to Day 0 through

      1 year after Treg dosing;

    • For males, from the day of Treg infusion (baseline visit) to three months after Treg infusion.
  • Use of an investigational therapeutic medication, or other biologic medications except rituximab, within the past 90 days, or 5 half-lives prior to screening, whichever is greater;
  • Concomitant medical condition that places the subject at risk by participating in this study, including but not limited to:

    • another severe, systemic autoimmune disease or condition (besides pemphigus) requiring systemic immunosuppressive therapy (e.g., rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), systemic sclerosis, primary Sjogren's syndrome, primary vasculitis, psoriasis, multiple sclerosis, ankylosing spondylitis, and inflammatory bowel disease), or
    • severe, progressive, or poorly controlled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease, or
    • history of significant infection or recurrent infection that, in the investigator's opinion, places the subject at risk by participating in this study, or
    • any other concomitant medical condition that, in the investigator's opinion, places the subject at risk by participating in this study.
  • Comorbidities requiring glucocorticoid therapy, including those which have required three or more courses of systemic glucocorticoids within the previous 12 months;
  • Current or history within the past year of substance abuse; or
  • Inability to comply with study and follow-up procedures.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03239470
Other Study ID Numbers  ICMJE DAIT APG01
APG01 ( Other Identifier: Autoimmunity Centers of Excellence (ACE) )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Institute of Allergy and Infectious Diseases (NIAID)
Study Sponsor  ICMJE National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators  ICMJE
  • Autoimmunity Centers of Excellence
  • Rho Federal Systems Division, Inc.
Investigators  ICMJE
Study Chair: Haley Naik, MD,MHSc University of California San Francisco School of Medicine: Department of Dermatology
Study Chair: Anna Haemel, MD University of California San Francisco School of Medicine: Department of Dermatology
Study Chair: Michael Rosenblum, MD, Ph.D. University of California San Francisco School of Medicine: Department of Dermatology
Study Chair: Jeffrey Bluestone, Ph.D. UCSF School of Medicine: UCSF Diabetes Clinic
Study Chair: David Wofsy, M.D. University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center
PRS Account National Institute of Allergy and Infectious Diseases (NIAID)
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP